Protective effects of L-carnitine on diabetic nephropathy in rats

doi:10.12092/j.issn.1009-2501.2019.03.007

Abstract

Abstract:

AIM: To investigate and analysis the protective effects of L-carnitine on diabetic nephropathy in rats. METHODS: Twenty-four 8-week-old male SD rats were randomly divided into three groups of 8 rats each. The control group were received single intraperitoneal injection of normal saline (10 mL/kg), followed by intravenously injection of normal saline (1 mL/kg). The diabetic nephropathy group were received single intraperitoneal injection of streptozotocin (65 mg/kg), followed by intravenously injection of normal saline(1 mL/kg). The experimental group were received single intraperitoneal injection of streptozotocin (65 mg/kg), followed by intravenously injection of intravenous L-carnitine (50 mg/kg), 1 time/d for 14 d, and the renal function after the experiment were recorded.RESULTS:The models of diabetic nephropathy were successfully established both in the experimental group and the diabetic nephropathy group. After the experiment, the body weight of the experimental group and the control group were significantly higher than that of the diabetic nephropathy group (P<0.05). Serum creatinine and urinary protein excretion, IL-6 and TNF-α, Bcl-2 and Caspase-3 in renal tissue of the experimental group and the control group were significantly lower than those of diabetic nephropathy group (P<0.05). There was no significant difference between the experimental group and the control group (P>0.05).CONCLUSION: The application of L-carnitine in diabetic nephropathy can effectively protect renal function, inhibit the expression of Bcl-2 and Caspase-3 in kidney tissue, and promote the recovery of normal body weight.

Key words: L-carnitine, rat, diabetic nephropathy, renal function

CLC Number:

ZHAO Shaojing, ZENG Yan, LI Zhengdong, ZHANG Hua. Protective effects of L-carnitine on diabetic nephropathy in rats[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(3): 278-282.

References

［1］Gholipur-Shahraki T, Feizi A, Mortazavi M, et al. Effects of carnitine on nutritional parameters in patients with chronic kidney disease: an updated systematic review and meta-analysis［J］. J Res Pharm Pract, 2018, 7(2): 57-68.
［2］俞晓忆, 周芷若, 谢媛, 等. 糖尿病肾病细胞模型三羧酸循环代谢异常和机制初探［J］. 中国临床药理学与治疗学, 2017, 22(5): 481-489.
［3］Niziol J, Bonifay V, Ossoliński K, et al. Metabolomic study of human tissue and urine in clear cell renal carcinoma by LC-HRMS and PLS-DA［J］. Anal Bioanal Chem, 2018, 410(16): 3859-3869.
［4］Ruoppolo M, Caterino M, Albano L, et al. Targeted metabolomic profiling in rat tissues reveals sex differences ［J］. Sci Rep, 2018, 8(1): 4663.
［5］Wang SJ, Yan CZ, Liu YM, et al. Late-onset cobalamin C deficiency Chinese sibling patients with neuropsychiatric presentations［J］. Metab Brain Dis, 2018, 33(3): 829-835.
［6］Nigam SK. The SLC22 transporter family: a paradigm for the impact of drug transporters on metabolic pathways, signaling, and disease ［J］. Annu Rev Pharmacol Toxicol, 2018, 6(58): 663-687.
［7］李瀚莹, 靳颖, 宫浩, 等. 左卡尼汀干预子痫前期大鼠肱动脉血管舒张功能效果评价［J］. 中国慢性病预防与控制, 2018, 26(2): 151-153.
［8］Janzen N, Hofmann AD, Schmidt G, et al. Non-invasive test using palmitate in patients with suspected fatty acid oxidation defects: disease-specific acylcarnitine patterns can help to establish the diagnosis ［J］. Orphanet J Rare Dis, 2017, 12(1): 187.
［9］李文川, 高良奎, 李浩航, 等. 左卡尼汀通过激活Nrf2/HO-1途径减轻大鼠肝脏热缺血再灌注损伤［J］. 中华肝胆外科杂志, 2017, 23(2): 121-125.
［10］Cucchiari D, Colombo I, Amato O, et al. Exertional rhabdomyolysis leading to acute kidney injury: when genetic defects are diagnosed in adult life ［J］. CEN Case Rep, 2018, 7(1): 62-65.
［11］Matsumoto M, Awano H, Bo R, et al. Renal insufficiency mimicking glutaric acidemia type 1 on newborn screening［J］. Pediatr Int, 2018, 60(1): 67-69.
［12］张媛媛, 张建荣, 耿燕秋, 等. 左卡尼汀通过激活Nrf2/ARE通路改善大鼠横纹肌溶解急性肾损伤［J］. 临床肾脏病杂志, 2017, 17(1): 53-57.
［13］Chou HC, Wen LL, Chang CC, et al. From the cover: l-carnitine via PPARγ- and Sirt1-dependent mechanisms attenuates epithelial-mesenchymal transition and renal fibrosis caused by perfluorooctanesulfonate ［J］.Toxicol Sci, 2017, 160(2): 217-229.
［14］赵丹丹, 李伟红, 刘迪. 左卡尼汀对心肌肥厚大鼠TGF-β/Smads信号通路和心肌能量代谢的影响［J］. 解放军医学院学报, 2016, 37(4): 395-398.
［15］Zhu M, Li Y, Zhou Z. Antibiotic ivermectin preferentially targets renal cancer through inducing mitochondrial dysfunction and oxidative damage ［J］. Biochem Biophys Res Commun, 2017, 492(3): 373-378.
［16］周涛, 向道康, 秦国伟, 等. St.Thomas No.2液添加左卡尼汀减轻老年大鼠离体心脏再灌注损伤［J］. 中国老年学杂志, 2014, 34(8): 2163-2165.
［17］Mohammadi M, Hajhossein Talasaz A, Alidoosti M, et al. Nephroprotective effects of L-carnitine against contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: a randomized open-labeled clinical trial［J］. J Tehran Heart Cent, 2017, 12(2): 57-64.
［18］王玲, 张美丹, 李若林, 等. 左卡尼汀对心力衰竭大鼠PPAR-α及三磷酸腺苷的影响［J］.中国医药导报, 2016, 13(32): 17-20.
［19］Ibarra-Sifuentes HR, Del Cueto-Aguilera , Gallegos-Arguijo DA, et al. Levocarnitine decreases intradialytic hypotension episodes: a randomized controlled trial ［J］. Ther Apher Dial, 2017, 21(5): 459-464.
［20］张美齐, 吴爱萍, 沈晔, 等. 左卡尼汀联合比索洛尔对内质网应激介导的心肺复苏后大鼠心肌损伤的影响［J］. 中华医学杂志, 2015, 95(19): 1475-1478.
［21］Shinozaki Y, Furuichi K, Toyama T, et al. Impairment of the carnitine/organic cation transporter 1-ergothioneine axis is mediated by intestinal transporter dysfunction in chronic kidney disease ［J］. Kidney Int, 2017, 92(6): 1356-1369.
［22］姜莉莉, 毛利民, 胡思佳, 等. 肾衰宁颗粒对糖尿病肾病大鼠肾组织NF-κB及PPAR-γ表达的影响［J］. 中国临床药理学与治疗学, 2018, 23(2): 132-137.
［23］Zeisel SH, Warrier M. Trimethylamine N-oxide, the microbiome, and heart and kidney disease ［J］. Annu Rev Nutr, 2017, 21(37): 157-181.

[1]	FU Xiaoyu, KONG Deguang, LI Juanjuan. Treatment progress of triple positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 866-875.
[2]	CHEN Qun, ZHU Heping, YUAN Xiaolong. Analysis of 197 cases of pentoxifylline injection and exploring supervision mode of rational drug use in hospitals [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 948-953.
[3]	FAN Jie, JIN Yongming, JIANG Xiaolong, JIANG Guohua. Molecular mechanism of lncRNA HOTAIR regulating miR-206 on the proliferation and apoptosis of rheumatoid arthritis synovial cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 736-742.
[4]	XU Xiuhe, HE Xiaoli, ZHOU Jiashun, PAN Lizhu, ZHOU Zhuojun, LI Jiayue, WANG Caixia, YUAN Wei, ZHU Guiqi. Effects of scacia honey on serum uric acid level and renal injury in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 743-750.
[5]	WANG Lin, YU Jianguo, LI Xiao, LUAN Jiajie. Establish and implement a pre-prescription system for outpatient based on Six Sigma DMAIC model [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 780-787.
[6]	WANG Anjing, WANG Yaya, LIANG Xuan, YAN Yajie, SU Jing, LI Caidong. Research progress on mechanisms and therapeutic drugs of peroxisome proliferator-activated receptor in treatment of cholestatic liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 796-808.
[7]	WANG Donghui, JIANG Suwen, HU Airong, ZHU Bo, HE Zheyun, ZHANG Lukan, WANG Jialan, FAN Ying, LIN Ken . Mulberry exerts antioxidant stress effect in rats with nonalcoholic fatty liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 609-616.
[8]	LI Hongqin, CAO Limin, JIN Manyi, WANG Jianlong, CHAI Xiaoping, TIAN Miaomiao. Effects of different dosage forms of Qianzheng powder on facial nerve injury in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 617-623.
[9]	ZHANG Wei, LIU Lei, GUAN Shaoyang, SHENG Zhao, SUN Wenwen. Analysis of the diagnostic value of fine-needle aspiration cytology and BRAF and RAS gene mutation screening for thyroid cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 653-657.
[10]	WU Xiongzhi, WANG Xuan, XU Siqi, JU Xia, WANG Shengbin, CHEN Yongquan. A comparative investigation of the impact of oral midazolam solution and dexmedetomidine nasal spray on preoperative anxiety in pediatric patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 666-670.
[11]	QIAO Hongliang, DING Ning, DENG Kaihong, LIU Binbin, DONG Chuanjiang, CHEN Xiaobo, ZOU Lili. New progress in research on novel control strategies for methicillin-resistant staphylococcus aureus infection [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 676-687.
[12]	CHEN Cheng, DENG Yu, GONG Youlan, ZHANG Zhenming, DUAN Wulei, QING Jun, ZHANG Bo. Research progress of the classical TCM formula Huaihua powder [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 697-704.
[13]	WANG Yan, ZHANG Jinhui, ZHAO Yongchen, LIU Hongxiang, LIU Yawei, MIAO Huanhuan, YANG Xincai. Sequoiaflavone inhibits stem cell properties such as proliferation and invasion of gastric cancer cells by down-regulating PI3K/AKT signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 508-513.
[14]	DANG Zilong, LIU Haiyang, ZHANG Yangfan, LIU Jinfeng, ZHANG Tianwei, LI Bin, GUO Hong, CHENG Wenyuan, XU Xiaohui, LI Yile, WEI Yuhui, WU Xin'an. Optimization strategy of antibiotic dosing regimen in intensive care unit patients with augmented renal clearance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 561-571.
[15]	LIU Tong, XU Jiaming, WANG Jinhuo, YIN Lei, CHEN Yongquan, GUO Jianrong. Changes of anesthetic drug concentration in plasma during isolation of autologous blood with acute isovolumic hemodilution and its influence on anesthetic effect after reinfusion [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 413-418.